Bend Bioscience Unites CoreRx and Societal CDMO Under Single Bend Bioscience Brand
September 4, 2024
Bend Bioscience has unified CoreRx and Societal CDMO under the Bend Bioscience brand to form an integrated contract development and manufacturing organization (CDMO). The consolidation combines CoreRx’s formulation development expertise, Societal CDMO’s scalable cGMP manufacturing and packaging capabilities, and Bend Bioscience’s research and technology to offer end-to-end development-to-commercialization services across facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia.
- Buyers
- Bend Bioscience
- Targets
- CoreRx, Societal CDMO
- Industry
- Pharmaceuticals
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Life Science Connect Acquires PharmaSource and CDMO Live
June 25, 2026
Media & Entertainment
Life Science Connect (LSC) acquired biopharma outsourcing service brands PharmaSource and CDMO Live from Life Science Networks. The deal combines PharmaSource and CDMO Live’s Europe and Americas divisions with LSC’s existing media platforms to create a single, expanded biopharma outsourcing platform and a new events division.
-
GI Partners Completes Acquisition of Charles River’s CDMO and Cell Solutions Businesses, Forms Rose BioSolutions
May 8, 2026
Healthcare Services
GI Partners completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories, creating an independent advanced therapy manufacturing company, Rose BioSolutions. Rose BioSolutions will provide end-to-end cell and gene therapy development and manufacturing, covering plasmid DNA, viral vectors, cell therapy production, and cellular starting materials.
-
BioCina and NovaCina Announce Strategic Merger to Create Integrated CDMO
January 13, 2025
Healthcare Services
BioCina and NovaCina announced a strategic merger that will create a fully integrated, end-to-end contract development and manufacturing organization (CDMO) under the BioCina name. The combined offering spans cell line and process development through clinical and commercial drug substance manufacturing and sterile fill-finish, leveraging BioCina’s Adelaide capabilities and NovaCina’s Perth sterile fill-finish plant.
-
CoreRx, Inc. Acquires Societal CDMO, Inc.
April 8, 2024
Pharmaceuticals
CoreRx, Inc. completed its acquisition of Societal CDMO, Inc. through a tender offer and subsequent short-form merger, acquiring approximately 92.8% of outstanding shares at $1.10 per share. Societal CDMO is now a wholly owned subsidiary of CoreRx and its common stock will be delisted from the Nasdaq Capital Market.
-
CoreRx Acquires Nucleo Life Sciences
May 24, 2021
Pharmaceuticals
CoreRx, Inc. has acquired Nucleo Life Sciences, a boutique CDMO based in San Rafael, California, expanding CoreRx’s US West Coast development presence and formulation capabilities. The deal, supported by CoreRx’s majority owner NovaQuest Private Equity and other shareholders, will integrate Nucleo’s Fast-to-Clinic formulation expertise (including spray-dried dispersions and NucleLoad) into CoreRx’s development and manufacturing platform.
-
NovaQuest Private Equity Acquires CoreRx, Inc.
January 19, 2021
Pharmaceuticals
NovaQuest Private Equity acquired CoreRx, Inc., a Clearwater, Florida–based contract development and manufacturing organization (CDMO). Affiliates of Signet Healthcare Partners will retain a minority stake; Goldman Sachs Specialty Lending Group provided debt financing. NovaQuest said the investment will support continued growth and capability expansion of CoreRx's clinical and commercial CDMO services.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.